PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-Cancer Drugs

E-ISSN： 1873-4286|16|12|1410-1416

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.16, Iss.12, 2010-04, pp. : 1410-1416

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications

Current Cancer Drug Targets, Vol. 8, Iss. 3, 2008-05 ,pp. : 187-198

Bentham Science Publishers

Access to resources Recommend Favorite

Involvement of PI3K/Akt Pathway in Prostate Cancer - Potential Strategies for Developing Targeted Therapies

Mini Reviews in Medicinal Chemistry, Vol. 5, Iss. 12, 2005-12 ,pp. : 1125-1132

Bentham Science Publishers

Access to resources Recommend Favorite

Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer

Current Medicinal Chemistry, Vol. 21, Iss. 26, 2014-09 ,pp. : 3070-3080

Bentham Science Publishers

Access to resources Recommend Favorite

PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress

Current Medicinal Chemistry, Vol. 17, Iss. 35, 2010-12 ,pp. : 4326-4341

Bentham Science Publishers

Access to resources Recommend Favorite

Oxygen-independent Regulation of HIF-1: Novel Involvement of PI3K/ AKT/mTOR Pathway in Cancer

Current Cancer Drug Targets, Vol. 13, Iss. 3, 2013-03 ,pp. : 245-251

Bentham Science Publishers

Access to resources Recommend Favorite